SOURCES SOUGHT
66 -- BZX700 Fluorescence Microscope Purchase
- Notice Date
- 1/3/2017
- Notice Type
- Sources Sought
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-CSB-HL-2017-060-KMA
- Archive Date
- 1/28/2017
- Point of Contact
- Kevin Alvarez,
- E-Mail Address
-
kevin.alvarez@nih.gov
(kevin.alvarez@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- A.Sources Sought Notice: NHLBI-CSB-HL-2017-060-KMA B.Title: BZX700 Fluorescence Microscope Purchase C.This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified business sources; and (2) their size classification relative to the North American Industry Classification System (NAICS) code 334516 for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method. All capability Statements sent in response to this SOURCES SOUGHT notice must be submitted electronically (via email) to Kevin Alvarez, Contract Specialist, at kevin.alvarez@nih.gov in either MS Word or Adobe Portable Document Format (PDF), by January 13, 2016 9:00 AM, EASTERN TIME under Solicitation Number: NHLBI-CSB-HL-2017-060-KMA. FAXES ARE NOT ACCEPTED. D.Information: 1.Background The National Heart, Lung, and Blood Institute (NHLBI) Sickle Cell Branch's (SCB) research examines the genetic factors underlying the phenotypic variability of sickle cell disease and beta thalassemia disorders. Both of these conditions are caused by mutations affecting the beta globin gene. A crucial difference between these conditions is that beta thalassemia results from a reduced number of red blood cells, while sickle cell disease results from abnormal "sickle" hemoglobin, or HbS, that makes red blood cells rigid and sickle-shaped, causing acute intermittent pain due to blockages of blood vessels and interruption of oxygen supply to vital organs. The rigid red blood cells are also very fragile and easily destroyed, causing a life-long anemia. HbF is the blood component primarily responsible for fetal oxygen transport and is present in infants until they are about 6 months old. The persistence of HbF beyond infancy is highly variable. High levels of HbF minimize many complications of sickle cell disease and can increase life expectancy. Drug therapy can reactivate HbF production in both children and adults, reducing the severity of sickle cell and beta thalassemia symptoms. SCB now hopes to identify and validate genetic and biomarkers that will allow early detection and monitoring of severe sickle cell complications, using new genome technologies and deep phenotyping. They plan to contribute to discovery and development of drugs designed for treatment of sickle cell disease, including those that promote HbF synthesis and inhibit HbS polymerisation. They specifically would like to explore targeting the 6q HBS1L-MYB intergenic enhancers as a genetic therapeutic approach for reactivating fetal hemoglobin. By gaining a deeper understanding of the pathophysiology of acute sickle pain, they hope to develop treatments to reduce severity and length of acute vaso-occlusive crises. 2.Purpose and Objectives The type of research that the SCB is conducting requires high quality and repeatable experiments using human neutrophils and other human cell lines commonly facilitated by conventional methods such as classical microscopy and multispectral flow cytometry. Unfortunately, such conventional methods are inconsistent and contain various levels of subjectivity. Such inconsistency and subjectivity are harmful to SCB's sensitive research. Keyence Corporation recently developed a novel system known as the BZX700 Fluorescence Microscope which significantly improves consistency and reproducibility. The BZX700 is the only system that can act as both an incubator and a deoxygenating chamber thus allowing the user to grow cells within the sealed system and control the cellular environment. The SCB needs to monitor the response of anti-sickling agents on red blood cells under low oxygen conditions, and the BZX700 is the only system that can facilitate this. The purchase of this microscope will allow the SCB to conduct more thorough and accurate experiments, enhancing their ability to fulfill their research mission. 3.Project Requirements The contractor shall provide the following equipment: •Fluorescence Microscope -Head (Item # BZ-X710) •Fluorescence Microscope -Controller (Item # BZ700E) •Win7 PC for BZ-X Dell T3420 (Item # 972080) •LCD Monitor for BZX (Item # 972072B) •BZ Training •Advanced Acquisition Module (Item # BZ-H3XD) •PC Software, analysis software for BZ Series (Item # BZ-H3AE) •Time-lapse Acquisition Module (Item # BZ-H3XT) •Measurement Module (Item # BZ-H3M) •PC Software, Hybrid Cell Count -License (Item # BZ-H3C) •Macro Cell Count Module (BZ-H3CM) •OPTICAL FILTER, DAPI FOR FLUORESCENCE MICROSCOPE (Item # OP-87762) •OPTICAL FILTER, GFP FOR FLUORESCENCE MICROSCOPE (Item # OP-87763) •OPTICAL FILTER, TEXAS RED FOR FLUORESCENCE MICROSCOPE (Item # OP-87765) •INU-KIW-F1 STAGE TOP INCUBATOR (Item # 972083) •OPTICAL FILTER, CY5 FOR FLUORESCENCE MICROSCOPE (Item # OP-87766) •CFI PLAN APO 2X LAMBDA Nikon Lens (2x) for BZ (Item # 972029) •CFI PLAN APO 10X LAMBDA Nikon Lens (10x) for BZ (Item # 972031) •CFI PLAN APO 20X LAMBDA Nikon Lens (20x) for BZ (Item # 972032) •Nikon Lens (20x ELWD Phase) for BZ S PI FI ELWD ADM 20xC (Item # 971962) •Nikon Lens (40x ELWD Phase) for BZ S PL FL ELWD ADM 40xC (Item # 971963) •CFI PLANAPO60XH LAMBDA Nikon Lens (60x oil) for BZ (Item # 972036) •NF50CC NIKON immersion oil (Item # 971806) •SIM-BASED SECTIONING MODULE INSTALLED IN BZ-X700E (Item # BZ-H3XF) •FILTER CUBE (Item # OP-87767) •3D ANALYSIS MODULE (Item # BZ-H3R) 4.Contractor Requirements Contractor must be able to provide the requested equipment. 5.Anticipated Period of Performance/Delivery Date Anticipated delivery date is 30-45 days after receipt of order. 6.Capability Statement Interested parties are expected to review this notice to familiarize itself with the requirements of this project. Failure to do so will be at your firm's own risk. The following information shall be included in the capability statement: a.A general overview of the respondents' opinions about the difficulty and /or feasibility of the potential requirement, and any information regarding innovative ideas or concepts. b.Information as needed in sufficient details of the respondents' (a) staff expertise, including their availability, experience, and formal and other training; (b) current in-house capability and capacity to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and management capability; and (e) examples of prior completed Government contracts, references, and other related information. c.The respondents' DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HUBZONE, etc) pursuant to the North American Industry Classification System (NAICS) code: 334516, Analytical Laboratory Instrument Manufacturing, Small Business Size 1,000 employees. d.Any other information that may be helpful in developing or finalizing the requirements of the potential acquisition. e.The capability statement shall not exceed 20 single-sided pages (including all attachments, resumes, charts, etc.) presented in single-space and using a 12-point font size minimum, in either Microsoft Word or Adobe Portable Document Format (PDF), with 8-1/2 by 11 inch paper size, and 1 inch top, bottom, left and right margins. f.All proprietary information should be marked as such. Statements should also include an indication of current certified small business status; this indication should be clearly marked on the first page of your capability statement (preferably placed under the eligible small business concern's name and address). Responses will be reviewed only by NIH personnel and will be held in a confidential manner. 7.Closing Statement All capability Statements sent in response to this SOURCES SOUGHT notice must be submitted electronically (via email) to Kevin Alvarez, Contract Specialist, at kevin.alvarez@nih.gov in either MS Word or Adobe Portable Document Format (PDF), by January 13, 2016 9:00 AM, EASTERN TIME under Solicitation Number: NHLBI-CSB-HL-2017-060-KMA. FAXES ARE NOT ACCEPTED. This Sources Sought Notice is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the National Heart, Lung, and Blood Institute (NHLBI). The NHLBI does not intend to award a contract on the basis of responses nor otherwise pay for the preparation of any information submitted. As a result of this notice, the NHLBI may issue a Request for Quote (RFQ). THERE IS NO SOLICITATION AVAILABLE AT THIS TIME. However, should such a requirement materialize, no basis for claims against NHLBI shall arise as a result of a response to this notice or the NHLBI's use of such information as either part of our evaluation process or in developing specifications for any subsequent requirement. "Disclaimer and Important Notes. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s)."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-CSB-HL-2017-060-KMA/listing.html)
- Record
- SN04362168-W 20170105/170103234357-322464e19bde2eccfb8b78ca97bc013f (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |